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Rheumatoid arthritis: pathological mechanisms and modern
pharmacologic therapies
Qiang Guo1,2, Yuxiang Wang1, Dan Xu2,3, Johannes Nossent3,4, Nathan J. Pavlos2 and Jiake Xu2
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily affects the lining of the synovial joints and is
associated with progressive disability, premature death, and socioeconomic burdens. A better understanding of how the
pathological mechanisms drive the deterioration of RA progress in individuals is urgently required in order to develop therapies
that will effectively treat patients at each stage of the disease progress. Here we dissect the etiology and pathology at specific
stages: (i) triggering, (ii) maturation, (iii) targeting, and (iv) fulminant stage, concomitant with hyperplastic synovium, cartilage
damage, bone erosion, and systemic consequences. Modern pharmacologic therapies (including conventional, biological, and
novel potential small molecule disease-modifying anti-rheumatic drugs) remain the mainstay of RA treatment and there has been
significant progress toward achieving disease remission without joint deformity. Despite this, a significant proportion of RA patients
do not effectively respond to the current therapies and thus new drugs are urgently required. This review discusses recent
advances of our understanding of RA pathogenesis, disease modifying drugs, and provides perspectives on next generation
therapeutics for RA.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic systemic autoimmune
disease that arises more frequently in females than males, being
predominantly observed in the elderly. The prevalence rate
reported in 2002 ranged from 0.5% to 1% of the population and
had regional variation.1 RA primarily affects the lining of the
synovial joints and can cause progressive disability, premature
death, and socioeconomic burdens. The clinical manifestations of
symmetrical joint involvement include arthralgia, swelling, red-
ness, and even limiting the range of motion. Early diagnosis is
considered as the key improvement index for the most desirable
outcomes (i.e., reduced joint destruction, less radiologic progres-
sion, no functional disability, and disease modifying anti-
rheumatic drugs (DMARD)-free remission) as well as cost-
effectiveness as the first 12 weeks after early symptoms occur is
regarded as the optimal therapeutic window.2–4 However, early
diagnosis remains challenging as it relies heavily on the clinical
information gathered from the patient’s history and physical
examination supported by blood tests, and imaging analysis. The
reasons for a delayed diagnosis vary markedly between countries
with differing healthcare systems,5 while the reasons for a delay in
initiating DMARD therapy in RA patients appear to be both
patient- and physician-dependent. Noticeably, patient awareness
of RA, the willingness of patients to seek medical advice, the time
for the patients from symptom onset to receiving appropriate
treatment, and the diagnostic capability of the physician all
influence the treatment and outcome of RA. With poorly
controlled or severe disease, there is risk that extra-articular
manifestations such as keratitis, pulmonary granulomas (rheuma-
toid nodules), pericarditis/pleuritis, small vessel vasculitis, and
other non-specific extra-articular symptoms will develop.
While there is currently no cure for RA, the treatment strategy
aims to expedite diagnosis and rapidly achieve a low disease
activity state (LDAS). There are many composite scales measuring
the disease activity such as the Disease Activity Score using 28
joints (DAS-28), Simplified Disease Activity Assessment Index
(SDAI), and Clinical Disease Assessment Index (CDAI).6 To achieve
full suppression of the activity of the disease (clinical remission),
rheumatologists need to monitor disease activity continuously
and accurately and to adjust the treatment regimen accordingly.
Universally applied pharmacologic therapy with non-steroidal
anti-inflammatory drugs (NSAIDs) and corticosteroids have proven
effective in relieving stiffness and pain, but do not moderate
disease progression. Over the last 20 years, the effectiveness of
DMARDs has gained much attention as these can efficiently
attenuate disease activity and substantially decrease and/or delay
joint deformity.7 The therapy classification includes the traditional
synthetic drugs, biological DMARDs, and novel potential small
molecules. Historical DMARDs such as auranofin, minocycline,
azathioprine, and cyclosporine are rarely implemented as modern
therapies. Several biological DMARDs have recently emerged
including TNF-inhibitor (Amjevita, Renflexis, Erelzi, Cyltezo, Imradl),
anti-CD20 antibody (Truxima, Rixathon), IL-6 receptor antibody
(Kevzara), RANKL antibody (Pralia), and JAK inhibitor (Olumiant).
Despite the increasing number of new drugs and treatment
regimes, complete long-term disease remission is not achieved for
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many patients and thus new therapeutic options are required. This
review provides a contemporary appraisal of recent literature on
the pathogenesis of RA and the potential of new pharmacological
interventions for optimizing RA treatment regimes.
PATHOGENESIS OF RA
There are two major subtypes of RA according to the presence or
absence of anti-citrullinated protein antibodies (ACPAs). Citrullina-
tion is catalyzed by the calcium-dependent enzyme peptidyl-
arginine-deiminase (PAD), changing a positively charged arginine
to a polar but neutral citrulline as the result of a post-translational
modification. ACPAs can be detected in approximately 67% of RA
patients and serve as a useful diagnostic reference for patients
with early, undifferentiated arthritis and provide an indication of
likely disease progression through to RA.8,9 The ACPA-positive
subset of RA has a more aggressive clinical phenotype compared
to ACPA-negative subset of RA.10 It is reported that ACPA-negative
RA has different genetic association patterns11 and differential
responses of immune cells to citrullinated antigens12 from those
of ACPA-positive subset. In terms of treatment,13–15 less effective
treatment response of methotrexate (MTX) or rituximab was
observed in ACPA-negative subset. This suggests a requirement
for future study on potential pathophysiology difference between
these two subsets. For the purpose of this review, we will focus on
the ACPA-positive subset of RA and divide the progression of RA
process into several distinct stages. It is noteworthy to mention,
however, that these stages may occur sequentially or
simultaneously.
TRIGGERING STAGE
The appearance of ACPA is now widely used to diagnose and
predict RA due to its high specificity (>97%) in clinical practice.
ACPA occurs as a result of an abnormal antibody response to a
range of citrullinated proteins, including fibrin, vimentin, fibro-
nectin, Epstein-Barr Nuclear Antigen 1 (EBNA-1), α-enolase, type II
collagen, and histones, all of which are distributed throughout the
whole body. ACPA production has been associated with genetic
and environmental factors. The strongest genetic risk factor
associated with ACPA-positive RA is found in genes encoding HLA-
DR, especially HLA-DR1 and HLA-DR4, also known as “shared
epitopes” (SEs).16 It is thought that SE influences RA outcome via
the production of ACPA and thus represents a primary risk factor
for ACPA production.17 The protein tyrosine phosphatase non-
receptor type 22 (PTPN22), which is a lymphoid specific protein
tyrosine phosphatase, has also drawn much attention because of
polymorphisms associated with ACPA-positive RA with the
contribution of PTPN22 to ACPA-positive RA among various
ethnicities.18–20 It may therefore act as a potent inhibitor of T cell
activation and in turn affect in the ACPA production. Genetic
variation of α1-antitrypsin has been found to be related to ACPA
production in RA.21 However, whether the production is directly
linked to α1-antitrypsin deficiency per se or results from altered
autophagy induced by the mutant α1-antitrypsin Z requires
further study. The increased response of type I interferon gene
associated with Th2 cell induction and B cell proliferation
correlates with ACPA production.22 Some researchers have
recently compared the gene expression profiles between ACPA-
positive RA and ACPA-negative RA patients.11,23 The critical
solution to the puzzle is the association between the discovered
genes and ACPA production. In addition, the risks of RA increase in
individuals with a family history of RA. The risk of developing RA
was three times higher in first-degree relatives of RA patients even
though familial factors influence RA in men and women
equally.24–26 It is also reflected in a twin study presenting
recurrence risks at 9.5–13.1 in monozygotic co-twins and at
6.4–11.7 in dizygotic same sexed co-twins as opposed to a
background population risk at only 0.37%.27 Another
study of 12,590 twins reveals that environment, lifestyle, and
stochastic factors may also play more important roles than
genetics in ACPA production while genetic factors are more
responsible for the progression from ACPA-positive individuals to
arthritis.28
The environment acts as a triggering factor for ACPA production
in RA and the epigenetic regulation combines environment with
genes. Gene–environment interaction influences the reactivity of
autoantibodies to citrullinated antigens in RA.29 ACPAs can be
detected long before the onset of the joint symptoms. This
phenomenon suggests that the joints may not be the triggering
spot for autoimmunity. Lung exposure to noxious agents,
including smoke, silica dust, nanosized silica, or carbon-derived
nanomaterials can trigger mucosal toll-like receptors (TLRs) that
activate Ca2+-mediated PADs, but also antigen-presenting cells
(APCs), such as classical dendritic cells (DCs) and B cells.30–32 The
coatomer subunit α gene mutations could disrupt the endoplas-
mic reticulum (ER)–Golgi transport and cause hereditary
autoimmune-mediated lung disease and arthritis, thereby provid-
ing a connection between the lung and the joint diseases.33
Moreover, smoking in the context of the HLA-DR SE gene may
trigger RA-specific immune reactions to citrullinated proteins.34
DNA methylation mediates smoking and genotype interaction in
ANPA-positive RA.35 There is ample evidence for three infectious
agents regarded as autoimmunity triggers in RA, namely
Porphyromonas gingivalis, Aggregatibacter actinomycetemcomi-
tans (Aa), and Epstein-Barr virus (EBV). The periodontal space can
also be a triggering site. In a clinic setting, 47% of the patients
with RA showed evidence of previous Aa infection compared with
11% in the control group. The pathogen Aa can secret leukotoxin
A and form pores in the neutrophil membranes that lead to
neutrophil hyper citrullination, which results in the release of
citrullinated autoantigens in the gums.36 P. gingivalis infection
leads to citrullinated autoantigens and the ACPA production in
two reported ways: one way is about PAD and arginine ginpains
(Rgps) of P. gingivalis, which can cleave proteins at arginine
residues and citrullinate proteins producing more neoantigens;37
another is about neutrophil extracellullar trap (NET) formation
induced by the P. gingivalis during the process of NETosis. ACPAs
induce NETosis and in turn NETosis provides citrullinated
autoantigens.38 EBV can affect ACPA-producing B cells and
impaired EBV control can be observed in RA.39 The intestinal
tract is another mucosal organ implicated in the pathogenesis of
RA because dysbiosis in RA patients can result from the
abundance of certain rare bacterial lineages. It is well documented
that gut microbiota may contribute to the pathogenesis of RA via
multiple molecular mechanisms.40,41 Several studies have estab-
lished the role of dietary factors in RA. The omega‑3 fatty acids
might not only lower the risk of ACPA production but also
prevent the onset of arthritis after detecting ACPAs.42 A healthier
diet can also make a contribution to reducing the risk
of ACPA-positive RA occurring at 55 years of age or younger.43
In addition, hormonal levels have been implicated in the
pathology of RA,44,45 but the association with ACPA has not been
firmly established. Alterations in gene expression regulation
through both microRNAs and long non-coding RNAs have been
proposed to contribute to the pathogenesis of RA. The contribu-
tion of other epigenetic modifications (e.g., sumoylation, histone
methylation, histone acetylation, and deacetylation) and their
functional role in RA currently remain unclear. Translation of
above observations to effective treatment and exploring their
interaction with the genome is challenging but would be
meaningful. It is of significance to clarify the detailed knowledge
of each risk factor in the triggering of RA so that tools can be
developed to provide susceptibility scores and early diagnosis, as
well as to identify new molecular targets for personalized
medicine (Fig. 1).
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MATURATION STAGE
This stage is initiated at the site of secondary lymphoid tissues or
bone marrow. Epitope spreading refers to the development of
immune responses to endogenous epitopes resulting from the
release of self-antigens. The immune response to autoantigens may
exist many years before disease onset and lay outside the joints. In
this stage, epitope spreading and a gradually increased titer of ACPA
can last several years before the onset of joint symptoms.46 Initial
ACCP levels appear to be of great importance in predicting the
interval time to disease onset.9 The production of ACPA reflects
break of immunological tolerance. As a result, many citrullination
neoantigens would activate MHC class II-dependent T cells that in
turn would help B cells produce more ACPA. ACPA can induce pain,
bone loss, and inflammation in RA.47,48 One study has identified that
two RA-specific autoantigens N-acetylglucosamine-6-sulfatase (GNS)
and filamin A (FLNA) correlate microbial immunity with autoimmune
responses in the joint.49 What is more, it has been proposed that
citrullination plays a unique role during osteoclast differentiation
and ACPA-induced osteoclast activation which might explain
important features of the gradual development of RA including
why the joints are targeted. Other likely factors include biologic
features of the targeted autoantigen, local microvascular, neurologic,
and biomechanical factors, and microtrauma-related mechanisms
may further contribute (Fig. 1).50
TARGETING STAGE
The involvement of RA in joints usually has a characteristic
presentation with synovitis occurring in symmetrical small joints.
Joint swelling is the external reflection of synovial membrane
inflammation following immune activation. The normal synovial
compartment is infiltrated by leukocytes and the synovial fluid is
inundated with pro-inflammatory mediators that interact to
produce an inflammatory cascade, which is characterized by the
interactions of fibroblast-like synoviocytes (FLSs) with the cells of
the innate immune system, including monocytes, macrophages,
mast cells, DCs, and so on, as well as cells of adaptive immune
system such as T lymphocytes (cell-mediated immunity) and B
cells (humoral immunity). The two immune systems and their
interactions are intimately involved in the development of ACPA-
positive RA, which results in the failed resolution of inflammation
(chronic synovitis). Monocytes/macrophages have been found to
massively infiltrate synovial membranes51 and be central to the
pathophysiology of inflammation. ACPA can enhance NF-kB
activity and TNF-α production in monocyte/macrophages via
binding to surface-expressed citrullinated Grp78.52 α-Enolase on
the surfaces of monocytes and macrophages induces production
of pro-inflammatory mediators.53 The imbalances between pro-
inflammatory M1 macrophage and anti-inflammatory M2 macro-
phage must also be considered in the context of inflammatory
RA.54 Indeed, a recent study reported that an imbalance in M1/M2
monocytes contributes to osteoclastogenesis in RA patients,
especially in ACPA-positive RA.55 Further, the pro-inflammatory
cytokine interleukin (IL)-17A in RA joint samples is localized
primarily to mast cells based on one study56 and mast cells can be
activated by ACPA and TLRs ligand.57 The accumulation of DCs in
the articular cavity has also been reported.58 As an APC, especially
myeloid DCs have been shown to induce T cell differentiation. A
detailed understanding of how myeloid DCs function in RA may
provide more effective RA treatment strategies. Other possible
innate immune pathways comprise neutrophil NETosis, nature
killer cell activation, etc. On the other hand, many researchers
place the adaptive immune system at the center of RA disease
pathogenesis. Most interest in the contribution of T cells has
focused on their antigen-driven role and cytokine release of
specific T cell subsets. CD4 effector T cells are major drivers of
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Fig. 1 RA can be triggered in the potential trigger sites (lung, oral, gut, et al.) by the interaction between the genes and environmental factors,
which is characterized by the onset of self-protein citrullination resulting in the production of autoantibodies against citrullinated peptides.
Lung exposure to noxious agents, infectious agents (Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, and Epstein-Barr
virus), gut microbiome, and dietary factors may induce the self-protein citrullination and maturation of ACPA. Citrullination is catalyzed by the
calcium-dependent enzyme PAD, changing a positively charged arginine to a polar but neutral citrulline as the result of a post-translational
modification. In RA, PAD can be secreted by the granulocyte and macrophage. ACPA occurs as a result of an abnormal antibody response to a
range of citrullinated proteins, including fibrin, vimentin, fibronectin, Epstein-Barr Nuclear Antigen 1, α-enolase, type II collagen, and histones,
all of which are distributed throughout the whole body. Many citrullination neoantigens would activate MHC class II-dependent T cells that in
turn would help B cells produce more ACPA. The stage is also called loss of tolerance. RA rheumatoid arthritis, PAD peptidyl-arginine-
deiminase, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor.
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abnormal immunity in RA by sustaining chronic synovitis and
supporting autoantibody production and a lack of reactive oxygen
species could boost pro-inflammatory T cells, which shed light on
the importance of energy metabolism in RA.59 As for B cells, the
research focuses on their antigen presentation, antibody forma-
tion and release, and cytokine release into the milieu. Therefore,
better understanding of the mechanisms of disordered innate
immunity, including immune complex-mediated complement
activation, adaptive immune responses against self-antigens, and
abnormal cytokine networks may open up new avenues to restore
immunologic homeostasis (Fig. 2).
FULMINANT STAGE
Hyperplastic synovium
Synovium is characterized by a mixture of bone marrow-derived
macrophages and specialized FLSs.60 Synovial cells maintain the
steady state of the joint by secreting hyaluronic acid and lubricin
for joint lubrication and function, as well as processing waste
products. In RA, the dysfunction of FLS leads to hyperplastic
synovium. The abnormal proliferation of FLS results from a loss of
contact inhibition that plays a critical role in RA by producing
inflammatory cytokines and proteinases, such as matrix metallo-
proteinases (MMPs) and tissue inhibitors of metalloproteinases
(TIMPs) that perpetuate joint destruction. They create a micro-
environment that allows for the survival of T cell and B cell and
neutrophil accumulation.61 Another hypothesis regarding the
cause of hyperplastic synovium is likely due to the resistance to
apoptosis associated with distinctive pathways. Such pathways
include abnormalities of tumor protein p53 function, which
contributes to synovial lining expansion and joint destruction in
RA;62 over expression of heat shock protein 70 and enhanced
activation of heat shock factor 1 in RA synovial tissues that foster
the survival of FLS.63 The pathogenetic mouse model synoviolin/
Hrd1 triggers synovial cell outgrowth through its anti-apoptotic
effects.64 It appears that synovial hyperplasia contains the
proliferation of resident slow-cycling cells, such as mesenchymal
stromal/stem cells and the infiltration of bone marrow-derived
cells in lethally irradiated mice after bone marrow transplanta-
tion.65 Although animal models of RA have been useful, they do
not always reliably replicate the human disease phenotype, even
less the ACPA-positive RA.
Cartilage damage
Cartilage acts as a key component of synovial joints, consisting of
chondrocytes and a dense and highly organized extracellular
matrix (ECM) synthesized by these chondrocytes and contains
type II collagen and glycosaminoglycans (GAGs). The hyperplastic
synovium causes major damage to the cartilage in RA through
directed adhesion and invasion. Conversely, inflammatory signals,
including those released from the ECM, can further stimulate FLS
activity. The mediators of cartilage damage include MMPs, a
disintegrin-like metalloprotease with thrombospondin type 1
motifs 4 and 5 and cathepsins. MMPs are synthesized by FLS
and can promote disassembly of the type II collagen network
causing biomechanical dysfunction. Membrane-type I MMP is
envisaged to be the predominant proteinase that degrades the
collagenous cartilage matrix.66 However, articular cartilage does
not have enough regenerative potential by itself. Consequently,
under the influence of synovial cytokines, particularly IL-1 and
17A, and reactive nitrogen intermediates, the cartilage is
progressively deprived of chondrocytes that undergo
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Fig. 2 Many cells and their cytokines play critical roles in the development of RA. The synovial compartment is infiltrated by leukocytes and
the synovial fluid is inundated with pro-inflammatory mediators that are produced to induce an inflammatory cascade, which is characterized
by interactions of fibroblast-like synoviocytes with the cells of the innate immune system, including monocytes, macrophages, mast cells,
dendritic cells, and so on, as well as cells of adaptive immune system such as T cells and B cells. Endothelial cells contribute to the extensive
angiogenesis. The fulminant stage contains hyperplastic synovium, cartilage damage, bone erosion, and systemic consequence. Bone
resorption virtually creates bone erosions, which are usually found at spots where the synovial membrane inserts into the periosteum, which
is known as a bare area according to certain anatomical features. The destruction of the subchondral bone can eventually result in the
degeneration of the articular cartilage as the result of a decrease in osteoblasts and an increase in osteoclasts and synoviocytes. IL interleukin,
TNF tumor necrosis factor, MMP matrix metalloproteinase, TGF transforming growth factor, PDGF platelet-derived growth factor, IFN
interferon, GM-CSF granulocyte–macrophage colony-stimulating factor, VEGF vascular endothelial growth factor, FGF fibroblast growth factor.
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apoptosis.50 This results in cartilage degradation demonstrable as
joint-space narrowing on radiography. These observations may
help explain why RA is a site-specific manifestation of a systemic
autoimmune disease, in which early cartilage damage in the
context of altered immune activation leads to a specific cellular
activation of FLS within the articular joints.67 Nevertheless, a better
understanding of the mechanisms underlying cartilage damage is
required.
Bone erosion
Bone loss is a pathological hallmark of RA and manifests as
localized, periarticular and systemic bone loss. Bone loss is the
result of the induction of osteoclasts and the suppression of
osteoblasts. “Periarticular” bone loss most likely refers to cellular
changes of the subchondral bone marrow, such as osteoclast
differentiation and the formation of inflammatory infiltrates. It
remains controversial whether inflammation or autoimmunity is
the key driver for bone damage. Evidence for the traditional
inflammatory theory is as follows: tumor necrosis factor alpha
(TNF-α), IL-6, IL-1β, IL-17, and other inflammatory cytokines
involved in RA could exert pro-osteoclastogenic effects and
suppress bone formation in the appropriate environment via
adequate signals, such as the receptor activator of nuclear factor
kappa-B ligand (RANKL) and macrophage colony-stimulating
factor (M-CSF).68 These promote the influx and differentiation of
the monocytes into osteoclasts in the context of inflammation,69
while anti-inflammation therapies for RA arrest the progression of
bone damage and vice versa.
The second possible pathway for bone loss in RA involves two
mechanisms for autoimmunity that act as a trigger for structural
bone damage. The first mechanism pertains to the formation of
immune complex and Fc-receptor-mediated osteoclast differen-
tiation. The second is the formation of anti-citrullinated vimentin
antibodies against the most citrullinated protein, making osteo-
clasts the ideal antigenic targets for anti-citrullinated protein
antibodies (ACPA). It is reported that ACPA binding to osteoclast
precursors induces osteoclastogenesis, bone resorption, and bone
loss.70 Bone resorption virtually creates a hole, which is usually
found at spots where the synovial membrane inserts into the
periosteum, which is known as a bare area according to certain
anatomical features. Subchondral bone plays a vital role in
maintaining the homeostasis of weight-bearing joints, and the
destruction of the subchondral bone can eventually result in the
degeneration of the articular cartilage. In the early stages of RA,
bone marrow edema is a common finding at the spot of
subchondral bone in humans,71 and aberrant transforming growth
factor-β (TGF-β) in the subchondral bone is involved at the onset
of RA joint destruction in animal models72 (Fig. 2).
Systemic consequences
Multiple studies have documented an elevated risk of cardiovas-
cular events in RA patients.73 The mechanisms responsible for this
risk may be related to cytokines that increase endothelial
activation and potentially make atheromatous plaques unstable.
Patients with active untreated RA have reduced total cholesterol,
low-density and high-density cholesterol.74 RA also influences the
brain by causing fatigue and reduced cognitive function; the lungs
by causing inflammatory and fibrotic disease; the exocrine glands
by causing secondary Sjogren’s syndrome; the skeletal muscles by
causing sarcopenia; and the bones by causing osteoporosis.
Finally, RA patients may be at greater risk of cancer, especially
hematologic and kidney cancers.75
MODERN RA PHARMACOLOGIC THERAPIES
The identification of a preclinical stage and a growing under-
standing of the natural history and mechanisms of RA develop-
ment, alongside new potential therapeutic interventions, shapes
the prospect that RA might be prevented in future.76 The current
treatment principles for established RA involve symptomatic
management and disease modification. A meta-analysis of 12
published studies confirmed that patients receiving delayed
DMARDs therapy were at higher risk of developing radiographic
joint space narrowing and bony erosions.77 In poorly controlled RA
patients, bony erosions become evident on radiographs
within 2 years of onset and these erosive changes are predictive
of poorer functional outcome.78 In a patient with otherwise
unexplained new onset polyarthritis, an urgent referral to a
rheumatologist is thus mandatory to confirm an RA diagnosis
and early initiation of a DMARDs-based treatment plan
aiming for disease remission with prevention of deformity. Oral
corticosteroids are potent and effective anti-inflammatory
drugs that may contribute to disease modification.79 However,
this needs to be weighed up against its well-known adverse
effects. Symptomatic management remains important throughout
the course of the disease and consists of everyday practical
measures to deal with the primary symptoms of joint stiffness,
such as pain and fatigue. Exercise is important to support joint
flexibility and function, while abstaining from smoking is a
universal advice to all RA patients given its impact on antibody
formation. (Table 1.)
CONVENTIONAL SYNTHETIC DMARDS (CS DMARDS)
Methotrexate
MTX is a modified form of folate designed to have an increased
binding affinity for dihydrofolate reductase (DHFR) compared with
its parent molecule. MTX is the cornerstone in the treatment of RA
either as a single agent or in combination with other DMARDs.80 In
a recent meta-analysis, MTX showed a substantial clinical and
statistically significant benefit compared to a placebo in the short-
term treatment of people with RA, although its use was associated
with a 16% discontinuation rate due to adverse side effects.81 Also,
radiographic progression rates measured by an increase in erosion
scores of more than 3 units were statistically significantly lower for
patients in the MTX group.82 MTX has been proposed to
participate in the process of folate antagonism, adenosine
signaling, the blocking of methyl-donor production involved in
reactive oxygen species, downregulation of the adhesion-
molecule expression, modification of cytokine profiles, and the
downregulation of eicosanoids and MMPs.83 Single nucleotide
polymorphisms (SNP) analysis and genome-wide association
studies (GWAS) have found some SNPs related to MTX respon-
siveness. For example, those located in the gamma-glutamyl
hydrolase (GGH), 5-aminoimidazole-4-carboxamide (ATIC), and
solute carrier family 19 member 1 (SLC19A1) genes.84 Never-
theless, the results from the studies are conflicting, and sufficiently
large genomic studies are needed to further develop the
understanding.
MTX for RA is administered as a low-dose (5–25mg) weekly
regimen with dosing conditional to the disease state and side
effects. Oral MTX has a more variable uptake than subcutaneous
administration, which also leads to fewer significant side effects.
Subcutaneous MTX administration also demonstrated a greater
bioavailability compared with oral MTX.85 MTX requires regular
monitoring to optimize dosing and assess its immunosuppressive
and hepatotoxic effects through frequent blood tests (monthly,
initially). There are a few well-established drug interactions for
MTX, including cotrimoxazole, which causes pancytopenia,
combined with azathioprine or leflunomide, which causes liver
and lung complications. NSAIDs can be safely used in conjunction
with MTX for symptom control after over 30 years of routine use of
the two agents. It is inconclusive that MTX enhances the risk of
malignancy beyond the increased relative risk of neoplasia
associated with RA per se.81 Despite this, the absolute risk is
low. Adverse effects associated with the use of MTX additionally
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Table 1. Modern pharmacologic therapies for rheumatoid arthritis
Classification Name Mechanism of
action
Potential mechanisms Side Effect Reference
Conventional
synthetic
DMARDs
Methotrexate Analog of folic acid Folate-dependent processes;
Adenosine signaling; Methyl-donor
production; Reactive oxygen species;
Adhesion-molecule expression;
Cytokine profiles Eicosanoids and
MMPs.
Increased liver enzymes, pulmonary
damage.
83
Leflunomide/
Teriflunomide
Pyrimidine synthesis
inhibitor
DHODH-dependent pathway;
Leukocyte adhesion; Rapidly dividing
cells; NF-kB; Kinases; Interleukins;
TGF-β.
Hypertension, diarrhea and nausea,
hepatotoxicity.
153
Sulfasalazine Anti-inflammatory
and
immunosuppression
Cyclooxygenase and PGE2;
Leukotriene production and
chemotaxis; Inflammatory cytokines
(IL-1, IL-6, TNF-α); Adenosine
signaling; NF-kB activation.
Gastrointestinal, central nervous
system, and hematologic adverse
effect.
154
Chloroquine
/Hydroxychloroquine
Immunomodulatory
effects
Toll-like receptors; Lysosomotropic
action; Monocyte-derived pro-
inflammatory cytokines; Anti-
inflammatory effects; Cellular
immune reactions; T cell responses;
Neutrophils; Cartilage metabolism
and degradation.
Gastrointestinal tract, skin, central
nervous system adverse effect and
retinal toxicity.
155
Biological DMARDs
Antibody-based therapies
TNF-α targeted
therapy
Infliximab TNF-α inhibitor Phagocytosis and pro-inflammatory
cytokines; Chemoattractant;
Adhesion molecules and
chemokines; Treg cell function;
Function of osteoclasts, leukocytes,
endothelial and synovial fibroblasts.
Infection (pneumonia and atypical
tuberculosis) injection-site reaction.
Adalimumab Hypertension.
Etanercept Severe /anaphylactoid transfusion
reaction.
156
Golimumab
Certolizumab pegol
B-cell targeted
therapy
Rituximab B cell depleting Fc receptor gamma-mediated
antibody-dependent cytotoxicity and
phagocytosis; Complement-
mediated cell lysis; antigen
presentation; B cell apoptosis;
Depletion of CD4+ T cells.
Infection, hypertension,
hypogammaglobulinemia, viral
reactivation, vaccination responses.
Ofatumumab Late-onset neutropenia.
Belimumab Inhibitors of B cell
function
Severe/anaphylactoid transfusion
reaction.
157
Atacicept
Tabalumab
T-cell targeted
therapy
Abatacept CD28/CTLA4 system Autoantigen recognition; Immune
cell infiltrate; T cells activation.
Infection, malignancy. 158
Belatacept CD80/CD86
Interleukin
targeted
therapy
Tocilizumab IL-6 inhibition Innate and the adaptive immune
system perturbation; Acute-phase
proteins.
Infections (most notably skin and
soft tissue), increases in serum
cholesterol, transient decreases in
neutrophil count and abnormal liver
function.
159
Anakinra IL-1 inhibition Inflammatory responses;
Matrixenzyme.
Injection site reactions, infections,
neutropenia, malignancy.Canakinumab 160
Rilonacept
Secukinumab IL-17 inhibition Mitochondrial function;
Autophagosome formation.
Infections, nasopharyngitis,
candidiasis, neutropenia, safety data
of mental health is limited.
161
Ixekizumab
Growth and
differentiation
factors
Denosumab RANKL inhibitor Maturation and activation of
osteoclast.
Low Ca2+ and phosphate in the
blood, muscle cramps, cellulitis, and
numbness.
162
Mavrilimumab GM-CSF inhibitor Activation, differentiation, and
survival of macrophages, dendritic
cells, and neutrophils; T helper 1/17
cell; modulation of pain pathways.
Safety file needs further research. 143
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include the development of accelerated nodulosis, also known as
MTX-induced accelerated nodulosis (MIAN), which occurs in
(1–10)% of patients on MTX.86 However, most adverse effects
can be reversed by supplementation with calcium or sodium
folinate.83
Leflunomide
Leflunomide reduces inflammation in the joints of RA patients by
inhibiting dihydroorotate enzymes essential for producing DNA
and RNA, particularly in activated proliferation lymphocytes. At
higher doses, the active metabolite teriflunomide also inhibits
tyrosine kinases responsible for early T-cell and B-cell signaling.87
Due to its different mechanism of action, Leflunomide is a
valuable addition to the armamentarium of drug treatment for RA
and is prescribed at a routine starting dose of 10 mg daily for the
initial 3 days followed by 20mg daily. Leflunomide has shown
clinical, functional, and structural efficacy similar to MTX88,89 and
has also been used effectively in combination with biological
agents. Dose reduction to 10 mg daily should be considered if side
effects occur, with the most common reported side effects being
diarrhea, nausea, headache, rash, itching, loss of hair and body
weight, hypertension, chest pain, palpitation, infection, and liver
failure. It is thus important to monitor gastrointestinal symptoms,
allergic reactions, alopecia, and liver function.90,91 There are a few
well-documented drug interactions, including cholestyramine that
impairs the absorption of Leflunomide, rifampin side effects
caused by raising Leflunomide levels in the blood, and
Leflunomide rarely increasing the anticoagulant effect of warfarin.
Leflunomide is deleterious to developing fetuses and breastfeed-
ing infants and therefore should be avoided during pregnancy
and lactation.92,93
Sulfasalazine (SSZ)
Owing to clinical trials, SSZ has been widely available as a
therapeutic agent for RA because of its anti-inflammatory and
antimicrobial activities. SSZ has significant efficacy in reducing
active joint counts and slowing radiographic progression, which is
comparable to the effects of Leflunomide.94,95 Its metabolites are
sulfapyridine and 5-aminosalicylic acid (5-ASA). SSZ has the ability
to increase the production of adenosine at the sites of
inflammation; inhibit osteoclast formation via modulatory effects
on the receptor activator of nuclear factor κβ (RANK), osteopro-
tegerin, and RANKL;96 inhibit TNF-α expression via the apoptosis of
macrophages,97 and suppress B-cell function.98 Sulfapyridine may
reduce IL-8 and monocyte chemotactic protein 1 (MCP-1)
secretions in inflammatory cytokines.99 The common adverse
effects of SSZ include gastrointestinal and central nervous system
toxicity, rash, liver function abnormalities, leukopenia and
agranulocytosis, megaloblastic anemia, oligospermia, and
infertility. The way to minimize the side effects is the slow
initiation of drug therapy and the serial monitoring of specific
laboratory tests. There are no major drug interactions reported but
patients should be cautioned about the risk and benefit ratio with
pregnancy and breastfeeding.100
Hydroxychloroquine
In RA, hydroxychloroquine is designed to interfere with the
interaction between T helper cells and antigen-presenting
macrophages that cause joint inflammation and decrease the
production of pro-inflammatory cytokines, thus reducing the
overall inflammatory response.101 Whereas, the classical explana-
tion is that, while hydroxychloroquine impaired phago/lysosomal
function, it also appears to work in a lysosome-independent
manner by impacting on intracellular TLRs, particularly TLR9, by
inhibiting the production of TNF, and by interfering with the
processing of the conversion of the membrane-bound pro-TNF
into soluble mature protein.102 Hydroxychloroquine has a gradual
onset action of 2–6 months, demonstrating improvement of long-
term functional outcome and retardation of radiographic
damage.103 The common adverse effects are predominantly
gastrointestinal, dermatological, and ophthalmologic. High dose
and long duration of use of hydroxychloroquine act as risk factors
for retinal toxicity which may progress even after cessation of
hydroxychloroquine. Therefore, effective screening is important
for early detection of retinal toxicity.104
BIOLOGICAL DMARDS (BDMARDS)
Although a somewhat vague definition, bDMARDs are a group of
drugs that target specific molecules or molecular pathways
involved in RA inflammatory processes. A number of bDMARDs
have been shown to have clinical and radiological efficacy in the
management of RA. TNF-α-inhibiting agents were the initial class
of bDMARDs with newer agents targeting B lymphocyte
antibodies CD-20, IL6, and CD28.105 (Fig. 3)
TNF-α inhibitor (TNFi)
TNF-α triggers inflammatory responses and is produced by
activated monocytes, macrophages, and T lymphocytes. TNF-α
acts through TNF receptors 1 and 2, which have some species
specificity and different affinity with TNF-α. Through the interac-
tion of TNFα and its receptors, key signaling pathways can be
activated, such as the NF-κB pathway, RANKL signaling, the
extracellular signal-regulated kinase (ERK) signaling pathway, the
tumor progression locus 2 (TPL2) pathway, and proapoptotic
signaling. TNF-α has been proposed to mediate local bone
destruction in the inflammatory musculoskeletal diseases due to
the increased TNF-α levels in these diseases.106 TNF has been
Table 1 continued
Classification Name Mechanism of
action
Potential mechanisms Side Effect Reference
Small molecules
JAK pathway Tofacitinib JAK1 and JAK3
inhibitor
T-cell activation, pro-inflammatory
cytokine production, synovial
inflammation, and structural joint
damage.
Zoster infection (advice is to
vaccinate beforehand) and other
potential side-effects should be
monitored carefully through further
study.
Baricitinib JAK1 and JAK2
inhibitor
163, 164
Filgotinib JAK1 inhibitor
Future drug
and target
Toll like receptors;165 Bruton’s tyrosine kinase;151 Phosphoinositide-3-kinase
pathway;166 Transforming growth factor-beta;167 Neuropathways;168 Dendritic
cell169
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involved in the process of endothelial cell activation, the induction
of metalloproteinases and adhesion molecules, angiogenesis, and
the regulation of fibroblast/keratinocyte/enterocyte chondrocyte/
osteoclast activation, as well as other inflammatory cytokines.
Current evidence implies that TNF-α antagonists may ease arterial
stiffness in RA.107 A substantial proportion of work-disabled
patients with RA who start anti-TNF therapy regain work ability.108
Compared with patients with RA receiving sDMARD therapy, TNFi
can decrease the risk of myocardial infarction.109 In the last 15
years, knowledge on the efficacy and toxicity of the TNFi has been
published and was mainly gathered through regional or national
registries created after these drugs reach the market. Based on the
currently available literature, TNFi has, therefore, become the first
choice of bDMARDs therapy in RA patients not responding to, or
intolerant of, a conventional sDMARD treatment.88 Despite
differences in biochemical and pharmacological properties of
the five currently approved TNFi, there does not seem to be a
clinically meaningful difference between them in terms of efficacy
and safety. In a large cohort of RA patients, anti-TNF-α therapy
does not increase the risk of serious bacterial infections compared
with MTX therapy.110 This leaves the choice of TNFi mainly
dependent on practicalities, such as dosing frequency or mode, or
on wider economic considerations. In recent years, numerous
biosimilar drugs have been developed, and some have already
been approved. A biosimilar (bio-originator) refers a biologic
medical product almost identical to an original product that is
often produced by another company.111
Infliximab (IFX) was the first TNFi for RA treatment and consists
of a recombinant chimeric monoclonal antibody composed of a
human antibody backbone with a mouse idiotype. It can
neutralize the biological activity of TNF-α by binding all forms of
TNF-α. IFX is administered by intravenous infusion and in overall
terms, IFX has an acceptable long-term safety profile.112 After the
treatment with IFX in RA, a decrease of the adhesion molecule,
IL-1, IL-6, IL-8, and MCP-1 was observed.113 Moreover, a reduced
thickness of the synovial lining layer could be found.114 The IFX
biosimilars include approved drugs in some countries, such as IFX-
dyyb, SB2, CT-P13, BOW015, NI-071, PF-06438179/GP1111, STI-002,
and ABP 710.113 IFX has adverse side effects, such as serious
infections, the reactivation of hepatitis B or tuberculosis, and the
risk of lymphoma and other cancers.
Adalimumab (Ada) is a fully humanized anti-TNF-α monoclonal
antibody given by subcutaneous route fortnightly and has a less
pronounced toxicity profile.115 Anti-Ada antibodies (AAA) are
detected in more than half of the treated patients with RA. The
AAA response is highly restricted and confined to the TNF-α
binding region of Ada, thereby neutralizing its therapeutic efficacy
and contributing to a loss of clinical efficacy.116 Ada is proven to
be a potent antirheumatic agent to achieve remission and inhibit
radiological progression. Furthermore, combination therapy with
MTX is superior to monotherapy. The Ada biosimilars include
drugs approved by some countries, such as ABP 501,117 Adfrar,
and ZRC-3197.113 Ada has the adverse side effects, such as skin
reactions, latent infections, and cardiac failure.
Etanercept is a recombinant protein composed of an immu-
noglobulin backbone and two naturally occurring soluble human
75-kDa TNF receptors. It is given by subcutaneous route twice
weekly with toxicity profiles similar to IFX and Ada.118 Etanercept
has shown sustained efficacy and function in rapidly decreasing
radiographic progression in elderly and younger patients with
RA  joint
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RA.24,119 The number of patients achieving clinical remission with
etanercept varies between 50% and 75% in the literature.
Etanercept biosimilars include the approved drugs SB4 and
GP2015.113
Golimumab is a human IgG1 kappa monoclonal antibody that
binds to both the soluble and transmembrane bioactive forms of
human TNF-α. It is administered once monthly by subcutaneous
injection. While the short-term safety profile is reasonable with no
differences in total adverse side effects, including serious
infections, cancers, tuberculosis, or deaths. However, long-term
surveillance studies are needed for further safety assessment.120
One-hundred milligrams of Golimumab showed numerically
higher incidences of serious infections, demyelinating events,
and lymphoma than 50mg of Golimubab does.121 The Golimu-
mab biosimilars include the BOW100 and ONS-3035, which are still
in the preclinical phase.113
Certolizumab pegol is a human anti-TNF-α antibody Fab
fragment that is chemically linked to polyethylene glycol and
neutralizes membrane-associated and soluble TNF-α. It is adminis-
tered every 2 weeks by subcutaneous injection and is well
tolerated. Certolizumab pegol biosimilars include the PF-688, a
drug still in preclinical phase testing.113 Significant side effects
occur in 2% of people who take certolizumab pegol.122
Incidentally, TNFi (namely onercept and lenercept) failed clinical
trials. However, TNF inhibitors have radically altered the approach
to treat RA and have become an integral part of disease
management. Medical professionals caring for patients should
have the basic knowledge of its adverse side effects. Nevertheless,
the inactivation of TNF signaling by rationally designed dominant-
negative TNF variants needs further investigation.123
B-Cell depletion and inhibition antibodies
Rituximab is a genetically engineered chimeric monoclonal anti-
body that targets CD20-positive B lymphocytes from early pre-B-
cells to later in the differentiation process, but it is absent in
terminally differentiated plasma cells. The binding to CD20 enables
rituximab to deplete subpopulations of B lymphocytes by way of
cell-mediation, complement-dependent cytotoxicity, and the
promotion of apoptosis and growth arrest. B lymphocytes may
contribute to the initiation and maintenance of the inflammatory
cascade by their action on antigen presentations and through the
production of pro-inflammatory cytokines, including IL-1, -4, -6, -8,
-10, and -12; TNF-α; vascular endothelial growth factor; MCP;
macrophage migration inhibitory factor; and the autoantibodies
rheumatoid factor (RF) and ACPA. It has been proposed that
Rituximab has an effect on CD4+ cells, inducing substantial T-cell
depletion in RA.124 Rituximab plus MTX demonstrated significant
and sustained effects on reducing joint damage progression in RA
patients who had a previously inadequate response to TNFi.125 The
Rituximab biosimilars include the drugs BCD-020, Maball, and
MabTas, which have been approved by some countries.113 The side
effects reported include hypogammaglobulinemia, infection, late-
onset neutropenia, and mucocutaneous reactions. Rituximab
treatment has been linked with rare cases of progressive multifocal
leukoencephalopathy (PML).
Belimumab is a monoclonal anti-B lymphocyte stimulator (BLyS)
antibody. It binds to soluble human BLyS with high affinity and
inhibits its biological activity. BLyS is elevated in the serum and
synovial fluid of patients with RA and is associated with increased
RF levels. The BLyS mechanism of action of is importance in the
survival of B cells, and its inhibition can lead to the apoptosis of
autoimmune B-cell clones.126 However, Belimumab was not
effective in phase II clinical trials for RA. Other promising CD-20
targeting antibodies (obinutuzumab, ibritumomab, ocaratuzu-
mab) need more clinical trials. The strategy of depth of depletion
of B cell populations may not be the better way compared with
the inhibition of B-cell modulatory cytokines.
T-Cell targeted therapies
Abatacept is a T-cell co-stimulation modulator and a fully human
soluble fusion protein that consists of the extracellular domain of
human CTLA-4, which is linked to the modified Fc part of human
IgG1. T-cells infiltrate into the synovial joint and increase the level of
pro-inflammatory cytokines such as interferon-γ and IL-17, causing
synovial cartilage and bone destruction. Upon antigen recognition,
T-cells require a costimulatory signal for full activation. Like the
natural CTLA4 molecule, abatacept interferes with CD80/CD86 with
higher avidity than CD28. Unlike other biologic drugs, it does not
inhibit inflammatory proteins but blocks the communication
between these cells by attaching to their surface. It is available in
an infusible or injectable form and is administered to patients who
have an inadequate response to one or more DMARDs. The data
available on abatacept suggests the risk of serious infections when
used together with the TNF-α blocker.127 Its side effects include
headaches, common colds, sore throat, nausea, and infection. By
contrast, targeting T cells using ciclosporin, anti-CD4 antibodies, anti-
CD5 antibodies, or alemtuzumab have not yielded clinically robust
responses in patients. The function of T cells and its subsets needs to
be further reexamined.128 Other T-cell medications, such as ALX-
0061, Sirukumab, Clazakizumab, Olokizumab, are still in the clinical
trial phase.
IL-6 inhibition
Tocilizumab (TCZ) is a humanized monoclonal antibody that
targets the IL-6 receptor, which is found on cell surfaces and in
circulation. IL-6 is produced by various cell types, including T cells,
B cells, monocytes, fibroblasts, and endothelial and synovial cells.
It has two receptors: mIL-6R (CD 126) and sIL-6R. In the pathology
of RA, IL-6 can stimulate pannus formation through increased
vascular endothelial growth factor expression and increase bone
resorption as a result of osteoclastogenesis, as well as oxidative
stress in leukocytes.129,130 TCZ is available in subcutaneous and
intravenous formulations. Its immunogenicity risk is low.131
Decreases in neutrophil counts in patients taking TCZ do not
appear to be associated with serious infections.132 Sirukumab, a
human monoclonal antibody binding to the IL-6 with high affinity,
also shows satisfied outcome with an expected safety profile in
clinical phase 3 study.133 It provides another valuable chance to
explore the effect of cytokine inhibition in RA rather than cytokine
receptor inhibition. The most common adverse effects observed in
clinical trials were upper respiratory tract infections, nasophar-
yngitis, headaches, and high blood pressure. The candidate IL-6
inhibitors currently undergoing clinical trials include sarilumab,
ALX-0061, MEDI5117, clazakizumab, and olokizumab. Clinical trial
data are promising and suggest that anti-IL-6 agents could be a
promising therapy.134,135
IL-1 inhibition
IL-1 is a cytokine that has the capability of immune and pro-
inflammatory actions. There are two specific immunoglobulin-like
membrane-bound IL-1 receptors, IL-1RI and IL-1RII. At the cell
surface, IL-RII, in contrast to IL-1RI, does not transmit signals and
acts instead as a decoy receptor that binds and inhibits IL-1. In
serum, both IL-1 receptors can bind IL-1, thereby regulating the
bioavailability of the cytokine.136
Anakinra (rHuIL-1ra) is a non-glycosylated recombinant form of
the IL-1 receptor antagonist used as a once daily injectable. It is
different from the native human protein by having an additional
N-terminal methionine. It decreases the activity of IL-1α and IL-1β
by binding to the IL-1 receptor. Its disadvantage includes the
requirement of daily injections, and an itchy rash may be observed
at the injection site. It can be used as a mono-therapeutic agent or
in combination with DMARDs. However, anakinra should not be
used in combination with anti-TNF agents. Its side effects include
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gastrointestinal tract reaction and allergy and infection of the
upper respiratory tract; thus, it should be monitored carefully.
Interestingly, RA patients receiving anakinra exhibited improved
cardiac contractility even within 3 h of a single administration.137
Therefore, Anakinra should be considered for patients with severe
or refractory pericardial disease and(or) heart failure.138 The
benefits of IL-1 inhibition in this population are worth further
exploration.
Other IL cytokines and their receptors have been studied as the
potential target: IL-17 inhibitor (Secukinumab) was finished in a
phase III study displaying improvement in patients with active RA
who had an inadequate response to TNF inhibitors.139 However,
IL-12/23 blockade, ustekinumab, did not see satisfying outcomes
despite being combined with MTX in a randomized phase II
study.140 The drugs targeting IL-7, 15, 18, 21, 32, and 33 are also in
a clinical trial.
Osteoclast differentiation factor
Denosumab (DMab) is a human monoclonal IgG2 antibody that
inhibits bone resorption by binding and inhibiting the receptor
activator of the NF-kB ligand (RANKL), an essential cytokine for
osteoclastogenesis and bone resorption. Briefly, RANKL is an
essential survival factor for DCs. RANKL-expressing Th17 cells
mediate bone resorption. In addition, RANKL secreted by memory
B cells promotes bone erosion in RA. Lastly, RANKL was known to
induce immune tolerance by promoting the differentiation of Treg
cells. It is conceivable that RANKL antagonists may influence
immune regulation. The interplay of activated immune cells,
synovial cell hyperplasia, and cytokine fosters an osteoclastogenic
environment fueled by TNF-α and RANKL. Indeed, the presence of
local and systemic bone loss in RA patients raised the possibility
that the inhibition of RANKL may be an effective strategy to limit
pathologic bone resorption.141 It has been proved that combining
denosumab with DMARDs may be considered for RA patients with
progressive bone erosions.142 Evidence from two phase II trials
and one randomized observational trial indicate that DMab
inhibits focal and systemic bone loss in RA. Phase III trials are
required to discern the magnitude of the inhibitory effect on bone
erosions and help to establish an optimal dose. The side effects
include low Ca2+ and phosphate levels in the blood, muscle
cramps, cellulitis, and numbness. Ultimately, DMab may prove to
be a promising drug in the treatment of RA.141 Besides, the phase
IIb study of a novel granulocyte–macrophage colony-stimulating
factor (GM-CSF) receptor alpha monoclonal antibody, mavrilimu-
mab, showed meaningful response by representing a novel
mechanism.143
SMALL-MOLECULE DMARDS
Small-molecule DMARDs revolutionize RA treatment. Many
cytokines use the Janus kinase (JAK) and signal transducer and
activator of transcription (STAT) pathway to exert their effect in
the pathology of RA, rendering them amenable to therapeutic
blockade with Jakinibs which have proven effective for the
treatment of RA.144 Jakinibs are being developed, and targeting
STATs as well as other intracellular signaling pathways may be a
future avenue for the treatment of RA, although substantial
challenges remain.
Tofacitinib is the first of a new class of oral drugs to have
synthetic small molecules that interfere with specific signal-
transduction pathway and is the third class of DMARD (tsDMARDs)
in RA treatment. It created the way to JAK inhibition in RA.
Tofacitinib preferentially inhibits JAK-3 and -1 over JAK-2. With an
oral bioavailability of 74% and mean elimination half-life of 3 h,
tofacitinib is metabolized via cytochrome P450 3A4 (CYP3A4) with
30% renally excreted; 5 mg bd Tofacitinib has recently been
approved by the FDA for moderate to severe RA refractory to
DMARDs based on recent efficacy studies, with the onset benefits
associated with the treatment occurring earlier.145 Common
adverse side effects were related to infection, hematologic and
hepatic disorders, and association of tofacitinib, with carcinogeni-
city and infections debatable.
Baricitinib is an orally administered molecular that inhibits JAK-1
and -2. It has moderate activity on tyrosine kinase 2 (TYK2)and
negligible activity on JAK-3 in both enzymatic and cellular assays.
Baricitinib also proved effective in radiological progression.
Peficitinib showed a 14 times higher selectivity for JAK-1/-3 over
JAK-2. Filgotinib is a highly selective inhibitor of JAK-1 over JAK-2,
JAK-3, and TYK2 in biochemical and cell assays. ABT-494 is also a
JAK-1 selective Jakinib. Decernotinib that selectively inhibits JAK3
over the other JAK family members in both enzyme and cellular
assays. The new Jakinibs with more restricted JAK isoform
selectivity are now between phases 2 and 3 of clinical develop-
ment. It is advised that jakinibs will require clinical and laboratory
vigilance.146
FUTURE PERSPECTIVES
With a better understanding of the pathophysiology of RA, new
therapeutic approaches are emerging to provide precision
medicine for individuals. However, the function and adverse side
effects of these drugs will need to be carefully evaluated and used
reasonably. Gene therapy means that treating RA by inserting a
gene into a patient’s cells instead of using drugs.147 Targeting
gene therapy in RA is a treatment strategy that is still in very early
stages of development but could lead to new possibilities because
of treating a disease at its root. The availability of Notch1 targeting
siRNA delivery nanoparticles148 and TNF-α gene silencing using
polymerized siRNA/Thiolated Glycol Chitosan Nanoparticles149 has
been tested relatively successfully in an animal model. To prevent
disease onset or relapses, smoking cessation or avoiding body
exposure to environment risk factors is probably the easiest and
most cost-effective method. Autoimmunity (tolerance break)
develops years before the inflammatory phase of the disease,
which can be considered as a golden period for preventing
disease progression. Reestablishing immune tolerance and
immunological homeostasis are ambitious goals in the way to
overcome the disease. T cells and B cells can be targeted by
specific drugs in the future to achieve seroconversion or delay the
onset of joint destruction. Reduction of the function of APCs and
modification of the pro-inflammatory properties of antibodies are
being further developed.150 There is also a great interest in the
novel approaches that have the possibility of becoming vital
therapeutic targets, such as TLRs; Bruton’s tyrosine kinase;
phosphoinositide-3-kinase pathway; TGF-β; neuro pathways, and
DCs. Bruton’s tyrosine kinase is involved in various signaling
pathways downstream of the pre-B-cell receptor and FcR, which is
a promising therapeutic target for RA.151 The safety and
tolerability of the intravenous infusions of expanded adipose-
derived stem cells in refractory RA have been reported.152
(Table 1) In fact, new pathologic insight will support new avenues
for therapeutic development.
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